CAMP4 Therapeutics(CAMP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
CAMP4 Therapeutics
CAMP.US
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc.
1.927 T
CAMP.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking129/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE106.47%A
    • Profit Margin-1404.47%E
    • Gross Margin-1076.86%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-3.68%C
    • Total Assets YoY304.40%A
    • Net Assets YoY1749.53%A
  • Cash ScoreD
    • Cash Flow Margin-7.12%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreB
    • Gearing Ratio32.09%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cystinosis market to grow at 5.1% rate from 2025-2034. Established cysteamine treatments dominate, limited new options.

    Currently, the cystinosis treatment sector is primarily dominated by traditional cysteamine-based therapies, with minimal access to advanced, curative, or genuinely disease-altering alternatives. Nevertheless, new treatments are starting to revolutionize the field by focusing on...

    Unusual Whales·
    Unusual Whales·

    Merck: teams up with CEPI to make the Ebola vaccine more accessible in low-income countries

    Merck has partnered with CEPI to enhance the accessibility of its Ebola vaccine, Ervebo, in low-income countries. The $30 million initiative aims to improve manufacturing and distribution, increasing vaccine yield and shelf life. Collaborating with Hilleman Laboratories, the project will also consider differentiated pricing for public-sector buyers. Key improvements include enabling storage in standard refrigerators, facilitating distribution in remote areas. This partnership is part of a global effort to make epidemic vaccines more sustainable and strengthen outbreak response in vulnerable regions.

    marketscreener·
    US
    MRK
    -1.31%
    marketscreener·
    US
    MRK
    -1.31%

    Global Achromatopsia Market to reach USD 191.22 million by 2032 with 7.58% CAGR growth, highlights genetic advancements.

    Dublin - The global market for achromatopsia is projected to witness significant growth, with estimations indicating an increase from USD 121.99 million in 2026 to USD 191.22 million by 2032, representing a compound annual growth rate of 7.58%. This growth is attributed to advancements in genetic characterization, diagnostics, and treatment options within the field of achromatopsia. The market landscape for achromatopsia is outlined in a comprehensive research report available on ResearchAndMarkets.com.

    Unusual Whales·
    Unusual Whales·

    ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges

    ProImmune Ltd has announced the Mastering Immunity 2026 symposium, set for April 13-14, 2026, at the Oriental Riverside Hotel in Shanghai. This inaugural event will focus on immunogenicity challenges in drug development, featuring global leaders in biotherapeutics and regulatory authorities. The symposium aims to provide practical guidance for managing immunogenicity risks, which can significantly impact the success of drug programs. Notable speakers include experts from the FDA, Pfizer, and Roche. The event is positioned as essential for those involved in the biopharmaceutical industry in China.

    MorningStar·
    MorningStar·

    CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock | CAMP Stock News

    CAMP4 Therapeutics Corporation announced the pricing of its $30 million underwritten offering of 5,000,000 shares of common stock at $6.00 per share. The offering is expected to close on December 19, 2025. The proceeds will support development activities and general corporate purposes. Leerink Partners is the sole underwriter. A registration statement has been filed with the SEC. This press release contains forward-looking statements subject to risks and uncertainties.

    StockTitan·
    US
    CAMP
    +10.89%
    StockTitan·
    US
    CAMP
    +10.89%
    © 2026 Longbridge｜Disclaimer